How did HRTX's revenue and expenses shift in Q4 2024?

Heron Therapeutics (HRTX) experienced a significant increase in total revenue in Q4 2024, reaching $40.78 million compared to $29.56 million in the previous quarter, a growth of approximately 38%. However, the company's cost of goods sold also rose, from $6.62 million to $10.23 million, indicating a potential strain on profit margins due to increased production costs. The research and development (R&D) expenses remained stable at around $3.18 million, which is a positive sign as it suggests that the company has been able to manage its R&D efforts without significant changes in spending. The selling, general, and administrative (SG&A) expenses increased from $19.46 million to $23.2 million, which could be a result of higher operational costs or strategic investments in the business. Overall, while the revenue growth is positive, the increase in cost of goods sold and SG&A expenses highlights the importance of efficient cost management for the company's future profitability.

|code|Ticker|Name|GICS Industry|Date|Selling, General, and Administrative Expenses|Cost of Goods Sold|Total Revenue|market_code|
|---|---|---|---|---|---|---|---|---|
|HRTX|HRTX.O|Heron Therapeutics|Pharmaceuticals|2024 Q1|2.6416E7|8444000|3.467E7|186|
|HRTX|HRTX.O|Heron Therapeutics|Pharmaceuticals|2024 Q2|2.7519E7|1.0518E7|3.6024E7|186|
|HRTX|HRTX.O|Heron Therapeutics|Pharmaceuticals|2024 Q3|2.3345E7|9458000|3.281E7|186|
|HRTX|HRTX.O|Heron Therapeutics|Pharmaceuticals|2024 Q4|2.3202E7|1.0228E7|4.0781E7|186|